Hallmarks of response, resistance, and toxicity to immune checkpoint blockade

(Cell 184, 5309–5337; October 14, 2021) We have identified errors in Table 1 of the originally published version of this review. During preparation of Table 1, we mistakenly listed the all-cause event rate, rather than the indicated high-grade (3-5) treatment-related adverse event rate, for KEYNOTE-189/NCT02578680 and KEYNOTE-407/NCT02775435. Table 1 and references (PMIDs) related to the final reports of KEYNOTE-189/NCT02578680 and KEYNOTE-407/NCT02775435, which include treatment-related adverse event rates, have now been corrected online. The authors apologize for any confusion these errors may have caused. Hallmarks of response, resistance, and toxicity to immune checkpoint blockadeMorad et al.CellOctober 7, 2021In BriefImmune checkpoint blockade has revolutionized cancer therapeutics, but it doesn’t work for everyone. It may cause unacceptable immune-related adverse events, or tumors may fail to respond or develop resistance. We’re beginning to understand the biological reasons why. Full-Text PDF